Pleural mesothelioma (PMe): The evolving molecular knowledge of a rare and aggressive cancer

Manuel Rigon,Luciano Mutti,Michelangelo Campanella
DOI: https://doi.org/10.1002/1878-0261.13591
2024-03-10
Molecular Oncology
Abstract:Pleural mesothelioma (PMe) is a rare but lethal pathology in which the carcinogen asbestos has a proven causative role. Asbestos travels inside the lungs and airways to prime degeneration of mesothelioma cells. Pathogenic molecular mechanisms and pathways are here outlined as well as ways for clinical intervention for this malignancy, which remains untreatable. Mesothelioma is a type of late‐onset cancer that develops in cells covering the outer surface of organs. Although it can affect the peritoneum, heart, or testicles, it mainly targets the lining of the lungs, making pleural mesothelioma (PMe) the most common and widely studied mesothelioma type. PMe is caused by exposure to fibres of asbestos, which when inhaled leads to inflammation and scarring of the pleura. Despite the ban on asbestos by most Western countries, the incidence of PMe is on the rise, also facilitated by a lack of specific symptomatology and diagnostic methods. Therapeutic options are also limited to mainly palliative care, making this disease untreatable. Here we present an overview of biological aspects underlying PMe by listing genetic and molecular mechanisms behind its onset, aggressive nature, and fast‐paced progression. To this end, we report on the role of deubiquitinase BRCA1‐associated protein‐1 (BAP1), a tumour suppressor gene with a widely acknowledged role in the corrupted signalling and metabolism of PMe. This review aims to enhance our understanding of this devastating malignancy and propel efforts for its investigation.
oncology
What problem does this paper attempt to address?